Related Experiment Video
Updated: Mar 29, 2026
High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
Published on: March 22, 2011
Triple-controlled oncolytic adenovirus expressing melittin to exert inhibitory efficacy on hepatocellular carcinoma
Chun-Yu Qian1, Kai-Li Wang1, Fan-Fu Fang1
1Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical University Shanghai 200433, China.
Abstract:
Hepatocellular carcinoma (HCC) is a highly malignant disease, and its outcome of routine therapies is poor. Comprehensive treatment including gene therapy is an important way to improve patients' prognosis and survival. In this study, we successfully constructed a triple-controlled cancer-selective oncolytic adenovirus, QG511-HA-Melittin, carrying melittin gene, in which the hybrid promoter, hypoxia-response element (HRE)-AFP promoter, was used to control viral E1a expression targeting AFP-positive cancer cells in hypoxia microenviroment, and the E1b-55 kDa gene was deleted in cancer cells with p53-deficiency. The cytological experiments found that the viral replication of QG511-HA-Melittin was increased to 12800-folds in Hep3B cells within 48 h, and 130-folds in SMMC-7721, but the virus did not replicate in L-02 cells. QG511-HA-Melittin had a strong inhibition effect on AFP-positive HCC cell proliferation, such as Hep3B and HepG2, whereas, there was low or no inhibition effect of QG511-HA-Melittin on AFP-negative cancer cells SMMC-7721 and normal cells L-02. In the in vivo experiment, compared with the blank control group, QG511-HA-Melittin can significantly inhibit the growth of HCC xenografts (P<0.05). The survival of mice in QG511-HA-Melittin group was much longer than that of the blank control group. Both in vitro and in vivo experiments manifested that QG511-HA-Melittin exerts an inhibitory effect on HCC cells, which may provide a new strategy for HCC biotherapy.
Insights
A novel oncolytic adenovirus, QG511-HA-Melittin, shows promise for hepatocellular carcinoma (HCC) biotherapy. This engineered virus selectively targets and inhibits HCC cells, improving survival in preclinical models.
Area of Science:
- Oncolytic virotherapy
- Gene therapy
- Hepatocellular carcinoma research
Background:
- Hepatocellular carcinoma (HCC) is a deadly cancer with poor treatment outcomes.
- Gene therapy offers a promising avenue to improve patient prognosis and survival.
- Targeted oncolytic viruses represent a novel therapeutic strategy.
Purpose of the Study:
- To construct and evaluate a triple-controlled, cancer-selective oncolytic adenovirus (QG511-HA-Melittin) for HCC treatment.
- To assess the virus's efficacy in targeting AFP-positive HCC cells in hypoxic environments.
- To determine the therapeutic potential of QG511-HA-Melittin in vitro and in vivo.
Main Methods:
- Construction of QG511-HA-Melittin with a hybrid hypoxia-response element (HRE)-AFP promoter and E1b-55 kDa deletion.
- In vitro cytological experiments to evaluate viral replication and proliferation inhibition in HCC cell lines (Hep3B, HepG2, SMMC-7721) and normal cells (L-02).
- In vivo experiments using HCC xenografts in mice to assess tumor growth inhibition and survival rates.
Main Results:
- QG511-HA-Melittin demonstrated significantly increased viral replication in HCC cells (12800-folds in Hep3B, 130-folds in SMMC-7721) but not in normal cells (L-02).
- The oncolytic adenovirus exhibited strong inhibition of proliferation in AFP-positive HCC cells (Hep3B, HepG2) with minimal effect on AFP-negative cells and normal cells.
- In vivo studies showed significant inhibition of HCC xenograft growth and prolonged survival in mice treated with QG511-HA-Melittin compared to controls.
Conclusions:
- QG511-HA-Melittin effectively targets and inhibits hepatocellular carcinoma cells both in vitro and in vivo.
- The engineered oncolytic adenovirus demonstrates potential as a novel biotherapy strategy for HCC.
- This targeted approach offers a promising new direction for improving HCC treatment outcomes.
